STUDY OBJECTIVES 3.1. PRIMARY OBJECTIVES The primary and key secondary objectives are to:  Characterize the safety and tolerability of SL-701 and SL-701 in combination with bevacizumab  Estimate the percent of patients alive 12 months after the initiation of SL-701 and SL-701 in combination with bevacizumab (OS-12) 3.2. SECONDARY OBJECTIVES The secondary objectives are to:  Estimate the objective response rate (ORR)  Estimate the disease control rate (SD+PR+CR) at 6 months, 9 months and 12 months and duration and of disease control (DDC)  Estimate the duration of response (DR)  Estimate the percent of patients alive and progression-free-at 6 and 12 months (PFS-6 and PFS-12) after the initiation of SL-701  Estimate the distributions of progression-free survival (PFS) and overall survival (OS) 3.3. EXPLORATORY OBJECTIV ES The exploratory objectives are to:  Estimate the relationship between ORR and disease control to overall survival 3.4. BRIEF DESCRIPTION This is a multicenter, open label Phase 1/2 study evaluating the efficacy and safety of SL-701 as a treatment for recurrent GBM divided into 2 stages. Approximately 76 patients will be tre ated in the study, 46 in Stage 1 and 30 in Stage 2, men and women at least 18 years of age, all of whom must have shown unequivocal evidence of either a first tumor recurrence or progression during or following an initial treatment regimen before enrollment in this study. During Stage 1, patients will receive SL-701 with the vaccine adjuvants GM-CSF injection and imiquimod topical cream. The first 24 patients treated in Stage 1 will be subject to the toxicity DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 13 of 63 monitoring rules described below. Progression of disease and disease-related death will not be considered adverse events (AEs). During Stage 2, patients will receive SL-701 with the vaccine adjuvant poly-inosinic-poly-cytidylic acid stabilized with poly-lysine and carboxymethy l cellulose (poly-ICLC) and bevacizumab. Patients who consent to the study will have screening procedures completed (Days -13 to 0). In Stage 1, a complete dose of study treatment consists of the administration of a sequence of 3 agents —SL-701 emulsion injection, GM-CSF injection, and imiquimod topical cream. An additional dose of imiquimod cream will be applied at the same site by the patient 24 hours (h) later. Site staff will administer the study medications to the patients starting on D ay 1 and then again every 2 weeks through Study Week 22, followed by every 4 weeks until study end. In Stage 2, a complete dose of investigational drug consists of the administration of a sequence of 2 agents, SL-701 emulsion SC injection and poly-ICLC injection. In Stage 2, patients will also receive IV bevacizumab (10 mg/kg) administered every 2 weeks, subsequent to the administrati on of SL-701/poly-ICLC. SL-701/poly-ICLC will be administered twice weekly for the first 2 we eks, every 7 days during the subsequent 3 doses, and subsequently every 14 days for the subsequent 9 doses (16 doses total) through Study Week 22, followed by every 4 weeks (for SL-701/poly-ICLC) until study end (bevacizumab will continue to be administered every 2 weeks subsequent to Study Week 22). Tumor response assessments will be performed every 8 weeks after Day 1 through Week 24, at Week 34, and every 4 weeks thereafter. Each tumor response assessment will use modified Response Assessment in Neuro-Oncology (RANO) criteria (Wen 2010, Appendix 2) and information will be collected on the patient’s clinical status, functional neurological statu s and concomitant medications, including corticosteroid use. For comparative purposes, tumor response will also be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, v ersion 1.1 (Eisenhauer 2009, Appendix 3). Patients who are evaluable for objective response will also be followed for DR, and all treated patients will be followed for OS and PFS until assessment of the primary objectives is complete d. Safety assessments including physical examination, vital signs, hematology, serum chemistry, coagulation parameters, urinalysis and adverse event monitoring will be performed according to t he study event schedules shown in Appendix 1 (Stage 1) and Appendix 2 (Stage 2). 3.5. PATIENT SELECTION Patients must have shown unequivocal evidence of either a first tumor recurrence or progression during or following the initial treatment regimen prior to enrollment in this study, as evidenced by MRI or CT. 3.5.1.